ABSTRACT
INTRODUCTION
Nausea and vomiting is a side effect of chemotherapy that often arise. This is because chemotherapy is toxic to cells of the GI tract enterochromaffin causing inflammation and involves a variety of mechanisms including 5-HT 3 neurotransmitter, dopamine, NK-1, which causes nausea and vomiting center stimulation in the brain (Rojas & Barbara 2012) . According to the American Society of Clinical Oncology Clinical Practice (2011) suggested the use of antiemetics for chemotherapyinduced nausea and vomiting is a 5-HT 3 antagonist, a corticosteroid and an NK-1 receptor antagonists. Antiemetic was given based on levels of risk of nausea and vomiting associated with chemotherapy (Hesketh 2011) . In this case, the level of risk of nausea and vomiting associated with chemotherapy were divided into four groups based sitostatika, namely: a high risk of> 90%, 31-90% moderate risk, low risk of 10-30% and a minimum of> 10%. Corticosteroids single therapy is recommended to chemotherapy by the risk of nausea and vomiting is low, a combination of corticosteroids and antagonist 5-HT 3 is for the therapy recommended chemotherapy with the risk of nausea and vomiting being, and at the risk of nausea and vomiting higher recommended a combination of antagonist 5-HT 3 , corticosteroids, and the NK-1 receptor antagonists.
The combined use of cisplatin-paclitaxel and cisplatin5fluorouracil in the case of head neck surgical oncology at the inpatient section Head Neck Surgery and chemo room Sukardja Hospital Dr. Soetomo quite a lot. The combination sitostatika cause nausea and vomiting with high risk, so the management of nausea and vomiting treatment is given is a combination of 5-HT 3 antagonist, corticosteroid, and the NK-1 receptor antagonists. Antiemetic corticosteroids recommended is deksamethason because it is more glucocorticoids, while the 5-HT 3 antagonist is recommended ondansetron, granisetron, palonosentron, dolasetron, tropisetron, or ramosetron (Hesketh 2011) . There are 2 antiemetic 5-HT 3 antagonist ondansetron and the outstanding field that granisetron at a price not much different. Differences in pharmacokinetics and pharmacodynamics of ondansetron and granisetron affect its effectiveness in reducing nausea and vomiting due to chemotherapy. Ondansetron has a half-life (t ½) 6 hours, with 70% protein binding, in hepatic metabolism and eliminated mostly by feces and only <5% through the urine. While granisetron, duration of action (DOA) 24 hours, t ½ to 9 hours iv, bonding with protein 65%, on the basis hepatic metabolism and elimination via urine and feces (AHFS, 2011). Pharmacokinetic differences lead to affect the time of administration. Ondansetron is given twice a day and granisetron given the day only one (Basch et al, 2011) . In terms of pharmacodynamics, ondansetron and granisetron binding affinity to the 5-HT 3 receptor that is distinct PKI 8.19 and 8.91. Granisetron only has specific binding to the 5-HT 3 while ondansetron has ties with other receptors, namely 5-HT 1b , 5-HT 1C , α1-adrenergic, and µ-opioid receptor.
MATERIALS AND METHODS
This study was an experimental study using simple randomization. Inclusion criteria of the study sample are surgical patients KL new oncology, receiving chemotherapy with a high risk of nausea and vomiting combination of cisplatin-paclitaxel and cisplatin-fluorouracil, age range 20-60 years and received premedication combination antiemetic granisetron and ondansetron and dexamethasone or dexamethasone. Exclusion criteria in this study were patients with a history of gastrointestinal disorders, patients with a history of kidney disease stage 3, 4, and 5, patients with a history of liver disease and patients with metastases to the brain. Criteria drop out is the inclusion of patients with the condition of an allergic reaction or hypersensitivity due deksamethason, ondansetron and granisetron, or other medications used during the study.
The study was conducted in March 2015 -January 2016 at the Hospital Dr. Soetomo with a total sample of 31 patients. The sampling technique with consecutive samplings. Samples are grouped into two, namely the ondansetron-dexamethasone and granisetron-dexamethasone group. The allocation of subjects in each group is done by order of odd and even numbers. Then the determination of treatment received in groups of odd and even simple randomization method is to use the currency. Determination of the treatment received by the patient sample is a double-blind manner. Patients who meet the criteria of the sample, chemotherapy is given in accordance with standard operating procedures Head Neck Surgery. Award premedication is antiemetic ondansetron 8 mg twice a day while granisetron 1 mg once a day. Observations nausea, vomiting performed for 12 hours, beginning after the administration of cisplatin. At the 12th, conducted interviews to patients with the method of measurement Index of Nausea, vomiting and Retching (Rhodes, 1996 , Brearley, 2008 , Kim et al, 2007 , Wood et al 2010 . Then to compare the effectiveness of granisetron and ondansetron and dexamethasone with dexamethasone do different test. From the measurement results obtained INVR nausea and vomiting with the clinical picture of the condition of nausea, vomiting without removing any and vomiting with their respective assessment parameters. Table 2 shows the percentage of nausea profile in a group granisetron and ondansetron-dexamethasone-dexamethasone, the data showed granisetron-dexamethasone combination has a percentage of the number 0 is greater than ondansetron-dexamethasone on the three parameters of frequency, duration and severity. Table 3 shows the percentage of the profile without issuing any vomiting (retching) in a group-dexamethasone and granisetron ondansetron-dexamethasone, the data showed, ondansetron-dexamethasone combination has the numbers 0 percentage greater than granisetrondexamethasone in both frequency and severity parameters. Table 4 shows the percentage of profiles vomiting that occurs in group-dexamethasone and granisetron ondansetron-dexamethasone, the data shows the number 0 more represented by granisetron-dexa-methasone group than in the group of ondansetron-dexamethasone, in frequency, many, or severity.
RESULTS
At the score of INVR method, the effectiveness of nausea and vomiting are divided into 5 categories. The first category is not happening nausea and vomiting with INVR value = 0. The second category is nausea vomiting with INVR value = 1-8. The third category is nausea and vomiting being the value INVR = 9-16. The fourth category is nausea vomiting weight to the value INVR = 17-24. The fifth category is extremely severe nausea and vomiting with a value INVR = 24-32. From the results, the percentage of comparative effectiveness of antiemetic ondansetron and granisetron in combination with dexamethasone in each category ( Figure 1 ). In the ondansetron-dexamethasone group, 53% did not happen nausea and vomiting, and 47% were mild nausea, vomiting. While in the granisetron-dexamethasone group obtained 64% do not occur nausea, vomiting and 29% were mild nausea, vomiting. In different test, because the data are not normally distributed then used a different test by using the MannWhitney. The results showed that there is no difference in effectiveness in reducing nausea and vomiting in the administration of granisetron and dexamethasone compared to administration of ondansetron and dexamethasone in the acute phase of chemotherapy patients with a high risk of nausea and vomiting (p = 0.076) (Figure 1 ). Further analysis used sitostatika influence the response of nausea and vomiting because in this study used two kinds of combinations sitostatika namely cisplatin-5 fluorouracil and cisplatin-paclitaxel. Figure 2 shows the percentage of nausea and vomiting caused by cisplatin-5 fluorouracil, with the number n in ondansetron-dexamethasone group were 12 patients and the number n in the granisetron group-dexamethasone was 9. The inci-dent did not occur nausea and vomiting ondan-setrondexamethasone group together with granisetron-dexamethasone is 66.7%. The same thing happened in the incidence of nausea and vomiting lightweight category is 33.3%. While the incidence of nausea and vomiting on a combination of cisplatin-paclitaxel (Figure 3 ) on the provision of antiemetic granisetron and dexamethasone with n = 5, show a good response that is 100% did not experience nausea and vomiting. While the administration of ondansetron and dexa-methasone with n = 5, the incident did not experience nausea and vomiting by 20% and the remaining 80% experiencing mild nausea and vomiting. 
DISCUSSION
The combination of cisplatin-paclitaxel and cisplatinfluorouracil is sitostatika first line therapy in surgical oncology KL. Cisplatin has a degree of nausea and vomiting> 90%, while sitostatika paclitaxel and fluorouracil have a degree of nausea and vomiting by 10% -30% (BCCA 2012). According to Hesketh, in addition to the degree of nausea and vomiting which is the distinctive character of the sitostatika, large doses of sitostatika also affect the response of nausea and vomiting. In addition, there are several other factors that affect namely: young and old age, a history of high alcohol consumption, and sex (Hesketh 2008) . Cisplatin dose of 50 mg/m2 or more can increase the risk of nausea and vomiting by 90% in patients who did not receive prophylactic antiemetics (Schnell 2003) . The use of cisplatin dose in surgical oncology KL is 100 mg/m2 included in the category of high-dose cisplatin, so that it can improve the patient's response to nausea and vomiting.
Conditions chemotherapy-induced nausea and vomiting caused by sitostatika menginflamasi enterochromafin cells activate the gastrointestinal tract and abdominal vagal afferents. The incoming signal to the vagal afferents and forwarded to the CTZ is then processed in the dorsal vagal complex that activates the deep abdominal muscles, diaphragm, stomach, and esophagus to occur response nausea and vomiting (Rojas & Barbara 2012). In addition to neuroanatomy, neuro-transmitters also have a role in triggering nausea and vomiting. A neurotransmitter that plays a major role is serotonin (5HT), substance P (SP), and dopamine. In studies comparing the effectiveness of this antiemetics, used a wide dose is 1 mg per antiemetic granisteron inj, inj ondansetron 8 mg and 8 mg dexamethasone, the recommended dose BCCA (Basch et al 2011 , Hoskins 2012 . The effectiveness of ondanetron and granisetron caused by several factors, namely pharmacokinetic and pharmacodynamic. In terms of pharmacokinetics, ondansetron has a half-life (t ½) 6 hours, 70% protein binding, hepatic metabolized and eliminated mostly by feces and only less than 5% through the urine. Granisetron, duration of action (DOA) 24 hours, t ½ to 9 hours, the bond with 65% protein, hepatic metabolized and eliminated through urine and feces (AHFS 2011). Pharmacokinetic differences affect the time of administration. Ondansetron is given twice a day and granisetron given the day only one (Basch et al, 2011) . In terms of pharmacodynamics, ondansetron and granisetron binding affinity to the 5-HT 3 receptors are expressed differently by PKI consecutive 8.19 and 8.91. Thus granisetron has the potential competitive binding with serotonin better compared with ondansetron. In addition, ondansetron has ties to other receptors, namely 5-HT 1b , 5-HT 1C ,α1-adrenergic, and µ-opioid receptor. So that ondansetron affinity divided to several other receptors than for 5-HT 3 receptor and potentially lead to the emergence of some of the side effects of medication. This is different from granisetron, which only has a binding affinity to the 5-HT 3 receptor (Schnell 2003) . Headache, constipation, diarrhea, somnolence and asthenia are the side effects of 5-HT 3 receptor antagonists (Aapro 2004 ).
Chemically, the 5-HT 3 receptor antagonists have a 3-dimensional space steric molecule that plays a role in drug binding to receptors called farmakofor. The third farmakofor is aromatic ring, a carbonyl group, and form clusters specific to each drug. In determining the binding affinity to the receptor, the carbonyl group is not an farmakofor that is important, but the aromatic ring. Ondansetron has the aromatic core Carbazole by affinity binding to 5-HT receptors only 250 to 500 times. This is because ondansetron also has ties with other receptors, namely 5-HT 1b , 5-HT 1c , α1-adrenergic, and µ receptor. Granisetron has indazole core which has a binding affinity to the 5-HT 3 receptor 4000 to 40 000 times higher than with other receptors (Mahesh et al 2004) .
In this study, 31 samples sejumah KL surgical oncology patients newly receiving chemotherapy, 17 patients receiving ondansetron-dexamethasone and 14 others received granisetron and dexamethasone therapy. Age range were sampled adult category, in order to avoid factors that increase the risk of nausea and vomiting. Of the existing patient demographics (Table 1) shows that KL surgical oncology patients is most prevalent in men than women. Riskesdas data by 2010, the incidence of head neck cancer more common in men than women by a ratio of 3:1. From demographic data obtained in this study, the number of men more than women is 2:1.
Nausea and vomiting of measurements obtained using INVR some parameter descriptions. From the measurement of nausea, there are three parameters: frequency, duration and severity. 0 at the frequency parameter granisetron nausea largest at-dexamethasone group by 77%, while in the ondansetron-dexamethasone group obtained a value of 56% (Table 1) . It shows that granisetron-dexamethasone group gives emphasis to the response of nausea greater than ondansetron. Table 2 frequencies occur mild nausea (figure 1) and moderate (figure 2) experienced by patients receiving antiemetic ondansetron-dexamethasone. But at the frequency parameters severe nausea, granisetron-dexamethasone group obtained a percentage of 8%. Something similar happened to the duration parameter. On the severity parameters obtained 8% with moderate nausea (figure 2) but not in conditions of severe nausea (3). The second data concluded that a combination antiemetic granisetron-dexamethasone combination can suppress nausea response greater than ondansetron-dexamethasone combination on all three parameters, frequency, duration and severity.
In Table 3 shows the profile without issuing any vomiting (retching), which consists of two parameters: the frequency and severity. In the ondansetrondexamethasone combination does not occur retching conditions (number 0) has a greater percentage than granisetron-dexamethasone in both parameters of frequency and severity at 94% and 86%. It shows that the incidence of vomiting without spending any less frequent in the combination of ondansetron and dexamethasone than granisetron and dexamethasone. Granisetron and dexamethasone group show experienced a frequency of vomiting without removing any of 7% for mild retching conditions (figure 1) and the conditions were retching (figure 2). It is also common in severity parameters. But at the ondansetron-dexamethasone group showed only mild retching (figure 1) by 6%.
Profile vomiting Figure 1 shows that the condition does not occur nausea and vomiting ondansetron-dexamethasone group was 53% and granisetron-dexamethasone group by 79%. This indicates that the granisetron group-dexamethasone can suppress nausea and vomiting response is greater than ondansetron-dexamethasone group.
From the Mann-Whitney analysis (Figure 1) showed that the combination of granisetron and dexamethasone was no difference in effectiveness in reducing nausea and vomiting than the acute phase of a combination of ondansetron and dexamethasone on pasein chemotherapy with a high risk of nausea and vomiting (p = 0.076). From some research on the comparative effectiveness of ondansetron and granisetron in combination with dexamethasone or not, gives a different picture. 3 mg granisetron and ondansetron 8 mg in combination with dexamethasone have the same effectiveness in preventing nausea and vomiting due to cisplatin doses> 50 mg/m3, but ondansetron is more cost-effective than granisetron (Italian Group antiemetics Research 1995). According to the Italian Group antiemetics Research, granisetron combination with dexamethasone is more effective for preventing chemotherapy-induced nausea and vomiting risk of nausea and vomiting were compared with the use of dexamethasone or granisetron alone (Italian Group antiemetics Research, 1995) . From the results of a metaanalysis of studies comparing several drugs 5-HT3 receptor antagonist for prophylaxis of acute nausea and vomiting due to chemotherapy. Combination chemotherapy-risk chemotherapy nausea and vomiting medium-high risk of nausea and vomiting with or without cisplatin demonstrated that granisetron has the same effectiveness with ondansetron. But at subanalisis i.v 3 mg granisetron compared with ondansetron 8 mg iv with non-cisplatin chemotherapy demonstrated that granisetron is effective in reducing nausea and vomiting compared to ondansetron (Jordan et al 2007) . According to Dempsey, a retrospective multicenter study, granisetron 1 mg or 10 mg/kg and 32 mg showed ondansetron was more effective than administration of ondansetron 8 mg in the prevention of acute nausea and vomiting phase cyclophosphamide therapy (Dempsey 2004). In another study also found that administration of granisetron plus dexamethasone proved to be more effective in controlling nausea and vomiting than the acute phase administration of granisetron only (Keyhanian 2012).
Furthermore, we want to know picture of the effectiveness of antiemetic ondansetron-dexamethasone and granisetron-dexamethasone based on the effect of each combination sitostatika (Figure 2) , the visible result of the effectiveness of ondansetron-dexamethasone (n = 12) and granisetron-dexamethasone balanced, suppression of nausea and vomiting was 66, 7% in the category does not occur nausea, vomiting and 33.3% in the category of mild nausea and vomiting. In the combination of cisplatin-paclitaxel (Figure 3 ) provision of antiemetic granisetron and dexamethasone (n = 5) showed a good response, ie 100% did not experience nausea and vomiting while the administration of ondansetron and dexamethasone (n = 5) of events did not experience nausea and vomiting just by 20% and the remaining 80% experiencing mild nausea and vomiting.
CONCLUSION
In the acute phase of chemotherapy patients with a high risk of nausea and vomiting administration of granisetron and deksmetason showed no difference in effectiveness in reducing nausea and vomiting than the delivery of ondansetron and dexamethasone (p = 0.076).
